Effects of Pancreatic kininogenase enteric-coated tablets combined with Epalrestat capsules in treatment of patients with diabetic peripheral neuropathy
Objective:To observe effects of Pancreatic kininogenase enteric-coated tablets combined with Epalrestat capsules in treatment of patients with diabetic peripheral neuropathy (DPN). Methods:The clinical data of 76 patients with DPN admitted to this hospital from August 2021 to May 2023 were retrospectively analyzed. According to different treatment options,they were divided into control group and study group,38 cases in each group. The control group was treated with Epalrestat capsules,while the study group was treated with Pancreatic kininogenase enteric-coated tablets on the basis of that of the control group. The clinical efficacy,the levels of hemorheology indexes (whole blood high shear viscosity,plasma viscosity,whole blood low shear viscosity,hematocrit),oxidative stress indexes[8-hydroxydeoxyguanosine (8-OHdG),malondialdehyde (MDA),superoxide dismutase (SOD),catalase (CAT)]and inflammatory factors[neurotensin peptide (PNT),C-X-C motif chemokine ligand 12 (CXCL12),interleukin-17 A (IL-17 A),C-C motif chemokine ligand 2 (CCL2)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups. Results:The total effective rate of the study group was 92.11％ (35/38),which was higher than 73.68％ (28/38) of the control group,and the difference was statistically significant (P<0.05). The levels of whole blood high shear viscosity,plasma viscosity,whole blood low shear viscosity and hematocrit in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant (P<0.05). The levels of 8-OHdG and MDA in the two groups were lower than those before the treatment,and those in the study group were lower than those in the control group;the levels of SOD and CAT in the two groups were higher than those before the treatment,and those in the study group were higher than those in the control group;and the differences were statistically significant (P<0.05). The serum PNT levels of the two groups were higher than those before the treatment,and that in the study group was higher than that in the control group;the levels of CXCL12,IL-17 A and CCL2 in the two groups were lower than those before the treatment,and those in the study group were lower than those in the control group;and the differences were statistically significant (P<0.05). However,there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusions:Pancreatic kininogenase enteric-coated tablets combined with Epalrestat capsules in the treatment of the DPN patients can improve the total effective rate of treatment and the levels of hemorheological indexes,and improve the levels of oxidative stress indexes and inflammatory factors. Moreover,it is superior to simple Epalrestat capsules treatment.
万方数据
维普
